Ultimately, the FDA approved the combination of AMD3100 and rHuG-CSF for the mobilization of HPSCs for autologous transplantation in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).657 Beyond its established use in mobilizing hematopoietic stem cells for bone marrow transplantation, AMD3100 has also been explored as a therapeutic option in patients with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. This evidence concerns the gene CSF2 and non-Hodgkin lymphoma.